FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Cardio Indication Approved for Diabetes Drug

Aug. 31, 2017

The FDA has approved Novo Nordisk’s Victoza (liraglutide) as a type 2 diabetes drug that reduces the risk of heart attack and stroke.

The drug was approved by the FDA in 2010 for blood-sugar control. The latest approval adds its effect on cardiovascular risk to its benefits.

An injectable, Victoza is approved for adults with diabetes 2 or cardiovascular disease.

View today's stories